Long Term Investment, Biotech & High Yield Dividend Stocks

[califax]

Sunesis Launches Phase 3 VALOR Trial of Vosaroxin in AML

Date : 12/21/2010 @ 8:00AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals (SNSS)

http://ih.advfn.com/p.php?pid=nmona&article=45739543

unesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the first patient has been randomized and dosed with blinded study treatment in its pivotal Phase 3 VALOR trial of vosaroxin, the company's lead drug candidate, in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand.

...